Tryptamine Therapeutics (AU:TYP) has released an update.
Tryptamine Therapeutics Limited director Jason Carroll has increased his direct stake in the company through an on-market acquisition of 604,738 ordinary fully paid shares at $0.01983 each, totaling $11,990.02. Following the transaction, Carroll’s total direct holdings have risen to 36,750,000 ordinary shares. This financial move indicates a bolstering of the director’s confidence in the firm’s prospects.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.
